Who should use the Accelerate drug discovery workflow?
Teams or solo builders working on science & healthcare tasks who want a repeatable process instead of one-off tool experiments.
AI Workflow · Science & Healthcare
Practical execution plan for accelerate drug discovery with clear steps, mapped tools, and delivery-focused outcomes.
Deliverable outcome
A complete set of regulatory documents and literature summaries ready for submission or publication.
30-90 minutes
Includes setup plus initial result generation
Free to start
You can swap tools by pricing and policy requirements
A complete set of regulatory documents and literature summaries ready for submission or publication.
Use each step output as the input for the next stage
Step map
Instead of relying on a single generic AI model, this pipeline connects specialized tools to maximize quality. First, you'll use BenchSci to a validated list of 1-3 high-confidence drug targets with supporting evidence. Then, you pass the output to Insilico Medicine (Pharma.AI) to a shortlist of 10-20 optimized lead compounds with predicted activity and safety profiles. Then, you pass the output to Arctoris to 2-5 validated lead compounds with confirmed in vitro activity and acceptable toxicity. Then, you pass the output to BioAge Labs AI Platform to one lead candidate with demonstrated in vivo efficacy, acceptable pk, and no major safety signals. Then, you pass the output to scikit-learn to a biomarker-driven patient selection strategy and a refined clinical trial protocol. Then, you pass the output to ConcertAI to an approved ind and an active phase i trial with first patient dosed. Finally, BenchSci is used to a complete set of regulatory documents and literature summaries ready for submission or publication.
Define therapeutic hypothesis and target validation
A validated list of 1-3 high-confidence drug targets with supporting evidence.
Generate and optimize lead compounds
A shortlist of 10-20 optimized lead compounds with predicted activity and safety profiles.
Synthesize and test lead compounds in vitro
2-5 validated lead compounds with confirmed in vitro activity and acceptable toxicity.
Conduct preclinical in vivo efficacy and safety studies
One lead candidate with demonstrated in vivo efficacy, acceptable PK, and no major safety signals.
Analyze clinical data and real-world evidence
A biomarker-driven patient selection strategy and a refined clinical trial protocol.
Design and initiate Phase I clinical trial
An approved IND and an active Phase I trial with first patient dosed.
Summarize research papers and generate regulatory reports
A complete set of regulatory documents and literature summaries ready for submission or publication.
Start by identifying a disease area and a specific biological target (e.g., protein, gene) linked to the condition. Use literature mining, public databases (e.g., Open Targets, ChEMBL), and AI-driven target discovery platforms to prioritize targets with strong genetic and mechanistic evidence. Validate the target's relevance through in silico analysis (e.g., CRISPR screens, expression data) before proceeding.
Why BenchSci: BenchSci directly supports target identification and biomarker discovery, which aligns with the needs for therapeutic hypothesis definition and target validation.
Design small molecules or biologics against the validated target using generative AI models (e.g., REINVENT, MolGAN) and virtual screening. Iteratively optimize leads for potency, selectivity, and ADMET properties using predictive models and molecular docking. Prioritize top candidates for synthesis based on multi-parameter optimization scores.
Why Insilico Medicine (Pharma.AI): Insilico Medicine (Pharma.AI) offers de novo molecular generation and hit-to-lead optimization, directly addressing lead compound generation and optimization needs.
Commission synthesis of top-ranked compounds (via internal lab or CRO) and run in vitro assays (e.g., binding affinity, cell-based efficacy, cytotoxicity). Use high-throughput screening (HTS) data to validate AI predictions and refine models. Select 2-5 best performers for further testing.
Why Arctoris: Arctoris provides automated lead optimization and high-throughput screening, which aligns with in vitro testing needs including assay data management.
Test the top 2-3 compounds in relevant animal models (e.g., mouse xenografts, disease models) to assess efficacy, pharmacokinetics (PK), and preliminary safety. Use AI-powered analysis of PK/PD data to optimize dosing regimens. Select one lead candidate for IND-enabling studies.
Why BioAge Labs AI Platform: BioAge Labs AI Platform supports biomarker discovery and clinical trial stratification, relevant for preclinical efficacy and safety studies.
Integrate historical clinical trial data, electronic health records (EHRs), and real-world evidence (RWE) to refine patient stratification and biomarker strategy. Use AI to identify subpopulations most likely to respond and to predict potential adverse events. This step informs the design of Phase I/II trials.
Why scikit-learn: scikit-learn directly provides classification, regression, and clustering tools needed for analyzing clinical data with Python/R and bioinformatics pipelines.
Prepare an Investigational New Drug (IND) application with all preclinical and CMC data. Design a first-in-human trial focusing on safety, tolerability, and dose escalation. Use adaptive trial designs and AI-based patient monitoring to accelerate enrollment and decision-making.
Why ConcertAI: ConcertAI offers cohort discovery and clinical trial optimization, directly supporting Phase I trial design and enrollment prediction.
Automatically extract key findings from published literature and internal reports using NLP tools (e.g., SciBERT, custom pipelines). Generate structured summaries for regulatory submissions, investigator brochures, and publication drafts. Ensure compliance with FDA/EMA formatting standards.
Why BenchSci: BenchSci supports reagent selection validation and biomarker discovery, but its literature review capabilities align with summarizing research papers for regulatory reports.
§ Before you start
Teams or solo builders working on science & healthcare tasks who want a repeatable process instead of one-off tool experiments.
No. Start with the top pick for each step, then replace tools only if they do not fit your pricing, compliance, or output needs.
Open the mapped task page and compare top options side by side. Prioritize output quality, integration fit, and predictable cost before scaling.
§ Related
Track competitor moves and market shifts in real-time with automated intelligence gathering — so you always know what your rivals are doing.
Connect siloed business applications into a unified, AI-managed operational pipeline that eliminates manual handoffs between systems.
Analyze portfolios, backtest investment strategies, and receive AI-generated market signals — giving individual investors access to institutional-grade tools.